Xemed completes regulatory filings with Health Canada

The Office of Clinical Trials of Health Canada has issued its “No Objection Letter” to two clinical trial protocols developed by Xemed and its Canadian collaborators, clearing the way for a new international branch of its research investigations into clinical indications for its hyperpolarized 129Xe magnetic resonance imaging agent MagniXene™. Earlier in the summer, Xemed had submitted a “Drug Master File” on MagniXene™ to Health Canada to begin the two-step regulatory filing process.

The hyperpolarized gas human imaging team at University of Western Ontario, led by Dr. Grace Parraga of Robarts Research Institute.